EUVIMEDEUVIMED entdecken
Crossref

Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study

Joshua Szanyi, David J Price, Kylie S Carville, Mitch Batty, Sarah Yallop, Suellen Nicholson, Theo Karapanagiotidis, Stacey Rowe, Sheena Sullivan, Vinay Menon, Daniel West, Lakshmi Manoharan und 5 weitere

Communicable Diseases Intelligence · 2024

DOI: 10.33321/cdi.2024.48.28 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2024. Verfasst von Joshua Szanyi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, COVID-19 Vaccines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare serological evidence of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with linked coronavirus disease 2019 (COVID-19) case notification data in Victoria, Australia, and to determine in vitro SARS-CoV-2 neutralisation activity based on prior infection and vaccination history. Design, setting, participants: Four cross-sectional serological surveys were conducted between 30 June and 31 October 2022 (a period of Omicron BA.4/BA.5 dominance) using 1,974 residual serum samples obtained from the Victorian Infectious Diseases Reference Laboratory. Serological results were linked to COVID-19 case notification and vaccination data. Surrogate virus neutralisation testing was performed to obtain in vitro inhibition estimates by anti-nucleocapsid serostatus and COVID-19 vaccination history. Main outcome measures: Adjusted anti-SARS-CoV-2 spike and nucleocapsid seropositivity by sex, age and region of residence; adjusted proportion of cases notified by anti-nucleocapsid serostatus, age and number of COVID-19 vaccination doses received; adjusted percentage in vitro inhibition against wildtype and Omicron BA.4/BA.5 SARS-CoV-2 variants by anti-nucleocapsid serostatus and COVID-19 vaccination history.

Results

The prevalence of anti-SARS-CoV-2 nucleocapsid antibodies was inversely proportional to age. In October 2022, prevalence was 84% (95% confidence interval [95% CI]: 75–93%) among 18–29-year-olds, compared to 39% (95% CI: 27–52%) among ≥ 80-year-olds. In most age groups, approximately 40% of COVID-19 cases appear to have been notified via existing surveillance mechanisms. Case notification was highest among individuals older than 80 years and people who had received COVID-19 vaccine booster doses. In vitro neutralisation of Omicron BA.4/BA.5 sub-variants was highest for individuals with evidence of both prior infection and booster vaccination.

Conclusions

Under-notification of SARS-CoV-2 infections in the Victorian population is not uniform across age and vaccination strata. Seroprevalence data that give insights into case notification behaviour provide additional context for the interpretation of existing COVID-19 surveillance information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antibodies, ViralCOVID-19 VaccinesVaccinationHumansMaleFemaleVictoriaMiddle AgedAdultAgedAdolescentYoung AdultCross-Sectional StudiesSeroepidemiologic StudiesAged, 80 and overChildChild, PreschoolAge FactorsInfantAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antibodyseroprevalenceserosurveillancetestingvaccination

Substanzen

Antibodies, ViralCOVID-19 VaccinesAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.
  • Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia.
  • Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Department of Health Professions, University of San Francisco, San Francisco, California, US.
  • Victorian Department of Health, Melbourne, Victoria, Australia.

Zitieren

APA

Szanyi, J., Price, D. J., Carville, K. S., Batty, M., Yallop, S., Nicholson, S., Karapanagiotidis, T., Rowe, S., Sullivan, S., Menon, V., West, D., Manoharan, L., Copsey, E., Majumdar, S. S., Sutton, B., Williamson, D. A., & McVernon, J. (2024). Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2024.48.28

Vancouver

Szanyi J, Price DJ, Carville KS, Batty M, Yallop S, Nicholson S, et al. Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study. Communicable Diseases Intelligence. 2024. doi:10.33321/cdi.2024.48.28

BibTeX
@article{Szanyi2024,
  author = {Szanyi, Joshua and Price, David J and Carville, Kylie S and Batty, Mitch and Yallop, Sarah and Nicholson, Suellen and Karapanagiotidis, Theo and Rowe, Stacey and Sullivan, Sheena and Menon, Vinay and West, Daniel and Manoharan, Lakshmi and Copsey, Eliza and Majumdar, Suman S and Sutton, Brett and Williamson, Deborah A and McVernon, Jodie},
  title = {Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study},
  journal = {Communicable Diseases Intelligence},
  year = {2024},
  doi = {10.33321/cdi.2024.48.28}
}
Kostenlos starten →